Natalie S. Callander, MD

Articles by Natalie S. Callander, MD

$Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.$

Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy

ByNatalie S. Callander, MD

October 6th 2026

Natalie S. Callander, MD, discussed the rationale for combining selinexor, carfilzomib, subcutaneous isatuximab, and dexamethasone in relapsed/refractory myeloma.

$The Management of Relapsed and Refractory Multiple Myeloma$

The Management of Relapsed and Refractory Multiple Myeloma

ByZhubin J. Gahvari, MD, MS,Natalie S. Callander, MD

April 26th 2023

Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.

Latest Updated Articles

$The Management of Relapsed and Refractory Multiple Myeloma$
The Management of Relapsed and Refractory Multiple Myeloma
April 26th 2023

Natalie S. Callander, MD

Articles by Natalie S. Callander, MD

Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy

The Management of Relapsed and Refractory Multiple Myeloma

Latest Updated Articles

Trending on CancerNetwork

Expanding CAR T and Bispecific Antibody Research in HIV-Associated Lymphoma

Why High-Risk Stage I NSCLC Needs a Post-Surgical Vaccine Option

Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer

Rinatabart Sesutecan Elicits Responses in PROC Regardless of FRα Expression

How Emory Became the First Adopter of the Liberty Endovascular Robotic System